Results 161 to 170 of about 4,112 (266)

Mesopic microperimetry in Stargardt disease: Application and reliability

Acta Ophthalmologica, Volume 104, Issue 5, Page e544-e554, August 2026.
Abstract Purpose Mesopic microperimetry (mMP) is a promising functional endpoint in clinical trials for Stargardt disease type 1 (STGD1). This study evaluated the test–retest variability of mMP and influencing factors, which is essential for ensuring reliability in future STGD1 trials.
Sybren H. Kootstra, Jeroen A. A. H. Pas, Patty P. A. Dhooge, Steffen Schmitz‐Valckenberg, Maurizio Battaglia Parodi, Philipp Herrmann, Frank G. Holz, Andrew J. Lotery, Katarina Stingl, Thomas H. Wheeler‐Schilling, Camiel J. F. Boon, Carel B. Hoyng, Soraprazan Consortium   +12 more
wiley   +1 more source

Development of a standardized murine model for investigating cholesterol crystallization and deposition in the gallbladder wall: effects of dietary cholesterol and pharmacological modulation. [PDF]

Eur J Med Res
Gao X, Xu C, Gao W, Liu S, Zheng Y.
europepmc   +1 more source

Dynamics of Body Composition and Metabolic Risk in Adolescents With Obesity Under GLP‐1 Receptor Agonist Therapy

Acta Paediatrica, Volume 115, Issue 8, Page 1726-1736, August 2026.
ABSTRACT Aim To explore changes in body composition in adolescents with obesity treated with glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) and their association with metabolic syndrome (MetS) components. Methods This real‐world retrospective study included adolescents (12–18 years) with obesity who received multidisciplinary lifestyle‐based ...
Adar Lopez, Liat Perl, Eyal Cohen‐Sela, Ophir Borger, Yael Issan, Hagar Interator, Erez Azoulay, Hadar Moran‐Lev, Ronit Lubetzky, Shira Zelber‐Sagi, Yael Lebenthal, Avivit Brener   +11 more
wiley   +1 more source

The transient external granular layer in human foetal cerebellum: insights into neurogenesis, genetic regulation, and developmental disorders. [PDF]

Anat Cell Biol
Kausar A, Nayak SS, Marpalli S, Veeresh, George BM, Hosapatna M.   +5 more
europepmc   +1 more source

Safety and Pharmacokinetics of Single and Multiple Ascending Doses of Olamkicept up to 2400 mg in Healthy Men: Phase I, Randomized, Placebo‐Controlled, and Double‐Blind Trial

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
ABSTRACT Olamkicept is a first‐in‐class fully human fusion protein that selectively inhibits trans interleukin (IL)‐6 signaling. Previous phase I clinical trials demonstrated that single doses up to 750 mg and multiple doses up to 600 mg were safe and well tolerated in healthy men and women.
Stanislav Ignatenko, Alla Radicke, Katharina Bruzelius, Michael Falkenberg, Lars‐Erik Kyhl, Signe Møgelmose, Arjun Ravi, Philippe Pinton   +7 more
wiley   +1 more source

Performance Assessment of Portable SLAM-Based Systems for 3D Documentation of Historic Built Heritage. [PDF]

Sensors (Basel)
Bonora V, Colapietro M.
europepmc   +1 more source

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7073-7082, August 2026.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Modeling Synaptic Maturation From Growth Cone to Synapse in Human Organoids. [PDF]

J Neurochem
Øhlenschlæger MS, Criscuolo L, Jensen P, Lloyd-Davies Sánchez DJ, Sutcliffe M, Bhosale S, Bogetofte H, Tahir M, Jakobsen LA, Pihl M, Brewer J, Schwämmle V, Poulsen FR, Freude K, Lancaster MA, Robinson PJ, Larsen MR.   +16 more
europepmc   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 6595-6606, August 2026.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Development of an HRM-qRT-PCR platform for fast and cost-effective genotyping of infectious bronchitis virus in Egypt. [PDF]

Sci Rep
Ali A, Prince A, Aljuaydi SH, Yassin AM, Khalifa R, Dardir S, Moussa SZ.   +6 more
europepmc   +1 more source